What are the rules on importing peptides and GLP-1s in Estonia, Latvia and Lithuania?

The short answer

Estonia, Latvia and Lithuania are usually treated as one market. On peptide law they are not. Lithuania permits an individual to receive up to ten packages of medicine a month from outside the EU. Estonia prohibits the postal delivery of any internet-ordered medicine outright, and states plainly that ordering medicines from outside the European Economic Area is not allowed. Latvia allows six months' supply hand-carried from a third country — but drops that to fourteen days for growth hormone and its analogues.

That last rule is the pattern worth carrying: across all three countries, GH-related peptides are treated as a separate and much more restricted category than ordinary medicines, including GLP-1s.

Evidence tier: Tier 1 for statutes and regulator guidance we read directly. Several Baltic registers are JavaScript applications we could not open, and those gaps are marked rather than filled. Educational content, not medical or legal advice.

The key points:

• Estonia bans postal delivery of internet-ordered medicines, regardless of origin.
• Latvia caps GH analogues at 14 days' supply where ordinary medicines get six to twelve months.
• Lithuania is the most permissive, allowing ten packages a month from third countries.
• "Research use only" labelling makes receipt harder, not easier, under Estonian and Latvian law.
• Estonia's digital prescription system leaves an audit trail the patient and every clinician can see.

The three countries do not share a rule

Personal importation is national law, and the Baltic states diverge sharply despite the shared Baltic packaging procedure that puts three languages on the same box.

Estonia is the outlier in a way that catches people out: it does not draw the EU / non-EU line where you would expect. Its postal rules are one regime regardless of origin, and the thing that decides legality is not where the parcel came from but what kind of transaction it was.

Estonia: the transaction matters more than the border

Evidence tier: 1 — regulator guidance read directly.

Estonia permits medicines to be posted only from a private individual to a private individual, up to ten unopened retail packs per consignment, in manufacturer's packaging, within stated pack-size ceilings. Prescription medicines may be posted for personal use in a quantity not exceeding therapeutic need.

That sounds permissive until you read what sits alongside it. The tax and customs board separately prohibits ravimite postimüük — mail-order sale of medicines — and delivery by post or courier of medicines ordered over the internet. Ravimiamet reinforces it from the other side: ordering medicines from outside the European Economic Area is prohibited.

So a peptide or GLP-1 ordered from a website and posted to Estonia fails on two independent grounds. It is an internet-ordered medicine delivered by post, which is prohibited outright. And if it came from outside the EEA, the order itself was prohibited before the parcel moved. The ten-pack private-gift allowance does not rescue it, because a purchase from a vendor is not a gift between individuals.

Anabolic steroids are absolutely prohibited by post, alongside narcotics, psychotropics, blood components, cells and tissues.

There is also a packaging trap in Ravimiamet's own guidance worth knowing: a box of ten blisters of ten tablets is one hundred-count pack — but remove the blisters from the box and each counts as a separate pack, turning one into ten. Opened packs may not be posted at all.

And the "research use only" label makes things worse, not better. Estonian guidance treats that labelling as triggering a documentary requirement a private individual cannot satisfy. The disclaimer that vendors use to distance themselves from human use is, in Estonian law, the thing that removes the recipient's lawful basis for receipt.

One more feature that shapes behaviour. Estonia's digiretsept is among the most advanced prescription systems in Europe, and it functions as an oversight instrument. Prescribers are legally obliged to prescribe electronically into the central Retseptikeskus; dispensing requires a national ID code and photo ID; and every prescription and every access leaves an audit trail visible to the patient. There is essentially no way to obtain a prescription GLP-1 through the legal Estonian channel without it being recorded against your ID and visible to any clinician who looks.

Estonian cross-border e-prescriptions can be dispensed in Finland, Latvia, Lithuania, Poland, Spain, Portugal, Greece, Croatia, Cyprus and Czechia — but expressly not for anabolic steroids, narcotics, or medicines without an Estonian marketing authorisation. So the cross-border route does not open access to anything unavailable at home.

Latvia: fourteen days for growth hormone

Evidence tier: 1 — Veselības inspekcija guidance, updated 21 October 2025.

Latvia's hand-carry allowances are generous for ordinary medicines and then fall off a cliff for one category:

• 12 months' supply from an EEA state
• 6 months' supply from a third country
• 14 days' supply for anabolic steroids, testosterone, growth hormone or their analogues from the EU — and the import must be justified by a prescription or a document issued by a medical institution

Everything must be for personal use, in original packaging with the manufacturer and country of manufacture identifiable, with a purchase receipt or equivalent.

That fourteen-day rule is the single most useful fact on this page for anyone using GH-releasing peptides. It is roughly a twenty-fifth of the allowance for an ordinary medicine, it applies to analogues rather than a closed list of named compounds, and it requires documentation most people carrying research-grade product will not have.

Latvia also closes the online route completely. The health inspectorate states that only certain Latvian pharmacies may distribute non-prescription medicines online, and that pharmaceutical regulation makes no provision at all for the online supply of prescription medicines. There is no domestic e-commerce channel for a prescription product.

And the research-use framing fails here too, for a cleaner reason. Under Article 17(5) of the Farmācijas likums, only a licensed manufacturer, importer or wholesaler may import substances for non-medical purposes — research or development testing. A private individual is not an eligible importer of research substances. The label does not create a private research exemption; it names a category that private buyers are excluded from.

Lithuania: the most permissive, which is not the same as safe

Evidence tier: 2 — cross-country comparison; national list contents unverified.

Lithuania permits an individual to receive up to ten packages once per month from outside the EU, and permits intra-EU receipt for "individual needs" without a stated numeric cap. On paper this is among the most open regimes in Europe and stands in direct contrast to Estonia next door.

Two cautions before anyone reads that as a green light.

We found no documented seizure or enforcement record for Lithuania in the period searched. That is an absence of published evidence, not evidence that enforcement is light, and it should not be read as the latter.

And permissive import rules do not touch the separate question of whether a substance is controlled under doping or narcotics law. We were unable to confirm the contents of Lithuania's stipriai veikiančios medžiagos definition or the health ministry's doping list, so we make no claim about whether any specific peptide appears on either.

What this means for GH peptides specifically

Evidence tier: 1–2 — statutes and regulator guidance; individual list entries unverified.

The Baltic pattern matches what we found in the Nordics, reached by a different legal route.

In the Nordics, GH-releasing peptides fall under anti-doping statutes where possession itself can be a crime. In the Baltics the mechanism is import law rather than criminal law, but the effect points the same way: GH, testosterone, anabolic steroids and their analogues are carved out into a far more restrictive category than ordinary prescription medicines. Latvia caps them at fourteen days. Estonia bans anabolic steroids from the post entirely and excludes them from cross-border prescriptions.

GLP-1 drugs sit in the ordinary-medicine category throughout. As in the Nordics, the compound with the large safety literature and the approved label carries the lighter regulatory burden, and the obscure research peptide carries the heavier one.

Whether possession as distinct from import is criminalised in Latvia is the single most important question we could not resolve — likumi.lv truncated the relevant regulation at point 46 of roughly 171 on every route we tried. We are not going to guess at a criminal provision.

Reimbursement: frameworks confirmed, contents not

Evidence tier: 1 for the frameworks; the actual lists are unverified.

We can describe how reimbursement works in each country. We cannot tell you what is on the lists, because the lists themselves were unreachable.

Estonia operates four discount tiers — 50%, 75%, 90% and 100% — with a €3.50 patient own-share per reimbursed prescription plus the percentage co-payment and any amount above the reference price. Additional reimbursement kicks in above €100 and again above €300 of annual spend. The reimbursed-medicines list is revised quarterly, on 1 January, April, July and October, which makes it the fastest-dating fact on this page.

Latvia uses three diagnosis-based categories under Cabinet Regulation No. 899: 100% for chronic life-threatening disease, 75% where absence of the medicine impairs vital functions, 50% for conditions where the medicine maintains or improves health status.

Whether any GLP-1 appears on either country's reimbursed list, at what rate and for which indication, is unverified. The Estonian list is a ministerial regulation on a JavaScript-gated portal; the Latvian NVD list returned an empty page. The common assumption — type 2 diabetes reimbursed, obesity self-paid — is plausible and consistent with the rest of Europe, but we did not confirm it and will not print it as fact.

What we could not verify

• Whether possession of doping substances is criminalised in Latvia, and at what threshold. The governing regulation truncated on every host we tried.
• Which GLP-1 presentations are actually marketed in Estonia and Latvia. Both national registers are JavaScript applications.
• Whether any GLP-1 is reimbursed in Estonia or Latvia, at what rate, for which indication.
• What customs does with an intercepted parcel in any of the three countries. Not documented in any source we could reach.
• Lithuania's controlled-substance and doping list contents, and its enforcement record.
• Telehealth prescribing rules in all three.
• Estonian statute section numbering, taken from the regulator's own description rather than the consolidated text.

Limitations

This is educational content. It is not legal advice, and it is not medical advice.

• Estonia's reimbursement list changes quarterly. Verify before relying on anything here.
• We describe what is lawful, not what to do. Nothing here is guidance on obtaining unapproved medicines, and we name no vendors or sourcing routes.
• Absence of a documented enforcement record is not evidence of lenient enforcement, particularly for Lithuania.
• We make no claim about whether a specific named peptide appears on any Baltic list. We did not open those lists.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Three countries that share a packaging procedure do not share an import rule. Lithuania permits ten packages a month from outside the EU. Estonia prohibits the postal delivery of internet-ordered medicines entirely and bars EEA-external ordering at source. Latvia sits between them for ordinary medicines and then applies a fourteen-day ceiling to growth hormone and its analogues that has no equivalent in its general regime.

The consistent thread is the category split. Whatever the mechanism — Latvia's fourteen-day cap, Estonia's postal ban on anabolic steroids and its exclusion of them from cross-border prescriptions — GH-related peptides are handled as a distinct and much more restricted class than GLP-1s.

And in both Estonia and Latvia, the "research use only" label works against the buyer rather than for them. In Estonia it triggers documentation a private person cannot provide. In Latvia it names a category only licensed importers may bring in. The disclaimer that is supposed to create distance is, in Baltic law, the thing that removes your standing to receive the parcel.

Related on this site

• Peptides in the Nordics: import rules and doping law
• Are peptides legal in the European Union?
• Are peptides legal in 2026? The complete regulatory guide
• What peptides are available in the EU
• Where to buy peptides in the EU: the legitimate routes
• Research-grade vs pharmaceutical-grade vs compounded peptides
• Traveling with peptides

References

• Estonia, postal and hand-carried import: Ravimiamet, sending medicines; travelling with medicines; Maksu- ja Tolliamet, restricted and prohibited goods; internet pharmacy guidance.
• Estonia, prescriptions: Tervisekassa, digiretsept, updated 29 July 2026.
• Estonia, reimbursement framework: Tervisekassa, medicines, updated 2 January 2025 — four tiers, €3.50 own-share, quarterly list revision.
• Estonia, pharmacy ownership: Ravimiamet, pharmacies, updated 26 November 2025 — proviisor majority ownership since 1 April 2020, four-pharmacy cap, vertical-integration ban.
• Latvia, personal import quantities: Veselības inspekcija, pharmacy Q&A, updated 21 October 2025, citing Cabinet Regulation No. 416 — 12 months EEA, 6 months third country, 14 days for anabolic steroids, testosterone, growth hormone and analogues.
• Latvia, statutory basis: Farmācijas likums, consolidated to 29 May 2026 — Art. 17(1) marketing authorisation and falsification prohibition; Art. 17(5) research-purpose import restricted to licensed entities; Art. 20(2¹) unregistered medicines.
• Latvia, reimbursement framework: MK noteikumi Nr. 899 of 31 October 2006 — three diagnosis-based categories at 100%, 75% and 50%.
• Baltic packaging procedure: Ravimiamet, packaging labelling and the Baltic procedure.